
Timothy Cloughesy

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6538088/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated <i>MGMT</i> promoter: An international randomized phase III trial. Neuro-Oncology, 2023, 25, 123-134.	1.2	150
2	Characterization of cognitive function in survivors of diffuse gliomas using resting-state functional MRI (rs-fMRI). Brain Imaging and Behavior, 2022, 16, 239-251.	2.1	5
3	Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma. Clinical Cancer Research, 2022, 28, 585-593.	7.0	18
4	Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement. Clinical Cancer Research, 2022, 28, 594-602.	7.0	67
5	Diffusion MRI is an early biomarker of overall survival benefit in IDH wild-type recurrent glioblastoma treated with immune checkpoint inhibitors. Neuro-Oncology, 2022, 24, 1020-1028.	1.2	12
6	Volumetric measurements are preferred in the evaluation of mutant IDH inhibition in non-enhancing diffuse gliomas: Evidence from a phase I trial of ivosidenib. Neuro-Oncology, 2022, 24, 770-778.	1.2	28
7	Visualization of tumor heterogeneity and prediction of isocitrate dehydrogenase mutation status for human gliomas using multiparametric physiologic and metabolic MRI. Scientific Reports, 2022, 12, 1078.	3.3	5
8	Prognostic value of <i>O</i> 6-methylguanine-DNA methyltransferase methylation in isocitrate dehydrogenase mutant gliomas. Neuro-Oncology Advances, 2022, 4, vdac030.	0.7	7
9	Nivolumab plus radiotherapy with or without temozolomide in newly diagnosed glioblastoma: Results from exploratory phase I cohorts of CheckMate 143. Neuro-Oncology Advances, 2022, 4, vdac025.	0.7	18
10	Balancing Risk and Efficiency in Drug Development for Rare and Challenging Tumors: A New Paradigm for Glioma. Journal of Clinical Oncology, 2022, 40, 3510-3519.	1.6	7
11	Paradoxical Association Between Relative Cerebral Blood Volume Dynamics Following Chemoradiation and Increased Progression-Free Survival in Newly Diagnosed IDH Wild-Type MGMT Promoter Methylated Glioblastoma With Measurable Disease. Frontiers in Oncology, 2022, 12, 849993.	2.8	1
12	Hypothetical generalized framework for a new imaging endpoint of therapeutic activity in early phase clinical trials in brain tumors. Neuro-Oncology, 2022, 24, 1219-1229.	1.2	9
13	Radiographic Response Assessment Strategies for Early-Phase Brain Trials in Complex Tumor Types and Drug Combinations: from Digital "Flipbooks―to Control Systems Theory. Neurotherapeutics, 2022, 19, 1855-1868.	4.4	1
14	Daily functioning in glioma survivors: associations with cognitive function, psychological factorsÂand quality of life. CNS Oncology, 2022, 11, CNS84.	3.0	2
15	Diagnostic and Prognostic Value of pH- and Oxygen-Sensitive Magnetic Resonance Imaging in Glioma: A Retrospective Study. Cancers, 2022, 14, 2520.	3.7	2
16	Incidence, molecular characteristics, and imaging features of "clinically-defined pseudoprogression― in newly diagnosed glioblastoma treated with chemoradiation. Journal of Neuro-Oncology, 2022, 159, 509-518.	2.9	8
17	Radiographic read paradigms and the roles of the central imaging laboratory in neuro-oncology clinical trials. Neuro-Oncology, 2021, 23, 189-198.	1.2	11
18	Voxelwise and Patientwise Correlation of ¹⁸ F-FDOPA PET, Relative Cerebral Blood Volume, and Apparent Diffusion Coefficient in Treatment-NaÃ⁻ve Diffuse Gliomas with Different Molecular Subtypes. Journal of Nuclear Medicine, 2021, 62, 319-325.	5.0	13

#	Article	IF	CITATIONS
19	Relative oxygen extraction fraction (rOEF) MR imaging reveals higher hypoxia in human epidermal growth factor receptor (EGFR) amplified compared with non-amplified gliomas. Neuroradiology, 2021, 63, 857-868.	2.2	7
20	Validation of diffusion MRI as a biomarker for efficacy using randomized phase III trial of bevacizumab with or without VB-111 in recurrent glioblastoma. Neuro-Oncology Advances, 2021, 3, vdab082.	0.7	2
21	FoundationOne CDx testing accurately determines whole arm 1p19q codeletion status in gliomas. Neuro-Oncology Advances, 2021, 3, vdab017.	0.7	6
22	Dopamine Receptor Antagonists, Radiation, and Cholesterol Biosynthesis in Mouse Models of Glioblastoma. Journal of the National Cancer Institute, 2021, 113, 1094-1104.	6.3	16
23	Early results from the CODEL trial for anaplastic oligodendrogliomas: is temozolomide futile?. Neuro-Oncology, 2021, 23, 347-349.	1.2	4
24	Differentiating IDH status in human gliomas using machine learning and multiparametric MR/PET. Cancer Imaging, 2021, 21, 27.	2.8	13
25	Preferential tumor localization in relation to 18F-FDOPA uptake for lowerâ€grade gliomas. Journal of Neuro-Oncology, 2021, 152, 573-582.	2.9	2
26	Worse prognosis for IDH wild-type diffuse gliomas with larger residual biological tumor burden. Annals of Nuclear Medicine, 2021, 35, 1022-1029.	2.2	5
27	Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial. Clinical Cancer Research, 2021, 27, 4491-4499.	7.0	112
28	Resolution of tissue signatures of therapy response in patients with recurrent GBM treated with neoadjuvant anti-PD1. Nature Communications, 2021, 12, 4031.	12.8	21
29	Abstract LB125: Pharmacokinetics of paxalisib in phase 2 clinical study in glioblastoma (GBM) with unmethylated O6-methylguanine-methyltransferase (MGMT) promotor status. , 2021, , .		Ο
30	Therapeutic Response Assessment of High-Grade Gliomas During Early-Phase Drug Development in the Era of Molecular and Immunotherapies. Cancer Journal (Sudbury, Mass), 2021, 27, 395-403.	2.0	2
31	Leveraging external data in the design and analysis of clinical trials in neuro-oncology. Lancet Oncology, The, 2021, 22, e456-e465.	10.7	53
32	Unique challenges for glioblastoma immunotherapy—discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank. Neuro-Oncology, 2021, 23, 356-375.	1.2	59
33	Targeting glioblastoma signaling and metabolism with a re-purposed brain-penetrant drug. Cell Reports, 2021, 37, 109957.	6.4	38
34	ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma. Nature Cancer, 2021, 2, 1372-1386.	13.2	39
35	Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma. Nature Communications, 2021, 12, 6938.	12.8	93
36	"Aerobic glycolytic imaging―of human gliomas using combined pH-, oxygen-, and perfusion-weighted magnetic resonance imaging. Neurolmage: Clinical, 2021, 32, 102882.	2.7	8

#	Article	IF	CITATIONS
37	A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE). Neuro-Oncology, 2020, 22, 705-717.	1.2	47
38	Safety and efficacy of VB-111, an anticancer gene therapy, in patients with recurrent glioblastoma: results of a phase I/II study. Neuro-Oncology, 2020, 22, 694-704.	1.2	23
39	Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02. Neuro-Oncology Advances, 2020, 2, vdaa124.	0.7	5
40	Human IDH mutant 1p/19q co-deleted gliomas have low tumor acidity as evidenced by molecular MRI and PET: a retrospective study. Scientific Reports, 2020, 10, 11922.	3.3	23
41	Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma. JAMA Oncology, 2020, 6, 1939.	7.1	84
42	Multiparametric MR-PET measurements in hypermetabolic regions reflect differences in molecular status and tumor grade in treatment-naÃ ⁻ ve diffuse gliomas. Journal of Neuro-Oncology, 2020, 149, 337-346.	2.9	5
43	Decorin expression is associated with predictive diffusion MR phenotypes of anti-VEGF efficacy in glioblastoma. Scientific Reports, 2020, 10, 14819.	3.3	13
44	Diffusion Magnetic Resonance Imaging Phenotypes Predict Overall Survival Benefit From Bevacizumab or Surgery in Recurrent Glioblastoma With Large Tumor Burden. Neurosurgery, 2020, 87, 931-938.	1.1	14
45	Ivosidenib in Isocitrate Dehydrogenase 1 <i>–</i> Mutated Advanced Glioma. Journal of Clinical Oncology, 2020, 38, 3398-3406.	1.6	167
46	Consensus recommendations for a dynamic susceptibility contrast MRI protocol for use in high-grade gliomas. Neuro-Oncology, 2020, 22, 1262-1275.	1.2	109
47	Diffusion MRI changes in the anterior subventricular zone following chemoradiation in glioblastoma with posterior ventricular involvement. Journal of Neuro-Oncology, 2020, 147, 643-652.	2.9	5
48	Emerging immunotherapies for malignant glioma: from immunogenomics to cell therapy. Neuro-Oncology, 2020, 22, 1425-1438.	1.2	37
49	Rate of change in maximum 18F-FDOPA PET uptake and non-enhancing tumor volume predict malignant transformation and overall survival in low-grade gliomas. Journal of Neuro-Oncology, 2020, 147, 135-145.	2.9	12
50	First-in-Human Phase I Study to Evaluate the Brain-Penetrant PI3K/mTOR Inhibitor GDC-0084 in Patients with Progressive or Recurrent High-Grade Glioma. Clinical Cancer Research, 2020, 26, 1820-1828.	7.0	54
51	Development of a Potent Brain-Penetrant EGFR Tyrosine Kinase Inhibitor against Malignant Brain Tumors. ACS Medicinal Chemistry Letters, 2020, 11, 1799-1809.	2.8	17
52	The dopamine receptor antagonist trifluoperazine prevents phenotype conversion and improves survival in mouse models of glioblastoma. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 11085-11096.	7.1	33
53	Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro-Oncology, 2020, 22, 1073-1113.	1.2	543
54	Volumetric analysis of IDH-mutant lower-grade glioma: a natural history study of tumor growth rates before and after treatment. Neuro-Oncology, 2020, 22, 1822-1830.	1.2	23

#	Article	IF	CITATIONS
55	Multiparametric MR-PET Imaging Predicts Pharmacokinetics and Clinical Response to GDC-0084 in Patients with Recurrent High-Grade Glioma. Clinical Cancer Research, 2020, 26, 3135-3144.	7.0	7
56	THER-06. THERAPEUTIC EFFICACY OF RRV-MEDIATED PRODRUG ACTIVATOR GENE THERAPY IN CLINICAL TRIALS OF RECURRENT HIGH-GRADE GLIOMA AND IN MURINE ORTHOTOPIC MODELS OF INTRACEREBRAL GLIOMA AND INTRACEREBELLAR MEDULLOBLASTOMA. Neuro-Oncology, 2020, 22, iii472-iii472.	1.2	0
57	CTNI-38. PAMIPARIB IN COMBINATION WITH RADIATION THERAPY (RT) AND/OR TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED (ND) OR RECURRENT/REFRACTORY (R/R) GLIOBLASTOMA (GBM); PHASE 1B/2 STUDY UPDATE. Neuro-Oncology, 2020, 22, ii51-ii51.	1.2	1
58	Patterns of long-term survivorship following bevacizumab treatment for recurrent glioma: a case series. CNS Oncology, 2019, 8, CNS35.	3.0	7
59	Oncogene Amplification in Growth Factor Signaling Pathways Renders Cancers Dependent on Membrane Lipid Remodeling. Cell Metabolism, 2019, 30, 525-538.e8.	16.2	130
60	The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients. Neuro-Oncology, 2019, 21, 1498-1508.	1.2	49
61	Mechanisms of Resistance to EGFR Inhibition Reveal Metabolic Vulnerabilities in Human GBM. Molecular Cancer Therapeutics, 2019, 18, 1565-1576.	4.1	11
62	Somatostatin Receptor Ligand Therapy—A Potential Therapy for Neurocytoma. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2395-2402.	3.6	7
63	Association between Tumor Acidity and Hypervascularity in Human Gliomas Using pH-Weighted Amine Chemical Exchange Saturation Transfer Echo-Planar Imaging and Dynamic Susceptibility Contrast Perfusion MRI at 3T. American Journal of Neuroradiology, 2019, 40, 979-986.	2.4	24
64	Design and Evaluation of an External Control Arm Using Prior Clinical Trials and Real-World Data. Clinical Cancer Research, 2019, 25, 4993-5001.	7.0	57
65	To randomize, or not to randomize, that is the question: using data from prior clinical trials to guide future designs. Neuro-Oncology, 2019, 21, 1239-1249.	1.2	16
66	Metabolic characterization of human IDH mutant and wild type gliomas using simultaneous pH- and oxygen-sensitive molecular MRI. Neuro-Oncology, 2019, 21, 1184-1196.	1.2	28
67	SPINT2 is hypermethylated in both IDH1 mutated and wild-type glioblastomas, and exerts tumor suppression via reduction of c-Met activation. Journal of Neuro-Oncology, 2019, 142, 423-434.	2.9	8
68	Validation of vessel size imaging (VSI) in high-grade human gliomas using magnetic resonance imaging, image-guided biopsies, and quantitative immunohistochemistry. Scientific Reports, 2019, 9, 2846.	3.3	32
69	Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial. Journal of Clinical Oncology, 2019, 37, 741-750.	1.6	103
70	pH-weighted amine chemical exchange saturation transfer echoplanar imaging (CEST-EPI) as a potential early biomarker for bevacizumab failure in recurrent glioblastoma. Journal of Neuro-Oncology, 2019, 142, 587-595.	2.9	28
71	Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nature Medicine, 2019, 25, 477-486.	30.7	932
72	ACTR-66. A PHASE 1, OPEN-LABEL, PERIOPERATIVE STUDY OF IVOSIDENIB (AG-120) AND VORASIDENIB (AG-881) IN RECURRENT IDH1 MUTANT, LOW-GRADE GLIOMA: UPDATED RESULTS. Neuro-Oncology, 2019, 21, vi28-vi29.	1.2	17

#	Article	IF	CITATIONS
73	ATIM-49 (LTBK-01). AMG 596, A NOVEL ANTI-EGFRVIII BISPECIFIC T CELL ENGAGER (BITE®) MOLECULE FOR THE TREATMENT OF GLIOBLASTOMA (GBM): PLANNED INTERIM ANALYSIS IN RECURRENT GBM (RGBM). Neuro-Oncology, 2019, 21, vi283-vi283.	1.2	14
74	Expression of PD-1 by T Cells in Malignant Glioma Patients Reflects Exhaustion and Activation. Clinical Cancer Research, 2019, 25, 1913-1922.	7.0	57
75	The clinical trials landscape for glioblastoma: is it adequate to develop new treatments?. Neuro-Oncology, 2018, 20, 1034-1043.	1.2	100
76	18F-FDOPA PET and MRI characteristics correlate with degree of malignancy and predict survival in treatment-naÃ ⁻ ve gliomas: a cross-sectional study. Journal of Neuro-Oncology, 2018, 139, 399-409.	2.9	32
77	Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo. Neuro-Oncology, 2018, 20, 1525-1535.	1.2	15
78	Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma. Neuro-Oncology, 2018, 20, 1411-1418.	1.2	24
79	Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma. Neuro-Oncology, 2018, 20, 1240-1250.	1.2	64
80	Platform trials arrive on time for glioblastoma. Neuro-Oncology, 2018, 20, 723-725.	1.2	14
81	Simultaneous p <scp>H</scp> â€sensitive and oxygenâ€sensitive <scp>MRI</scp> of human gliomas at 3 <scp>T</scp> using multiâ€echo amine proton chemical exchange saturation transfer spinâ€andâ€gradient echo echoâ€planar imaging (<scp>CESTâ€SAGEâ€EPI</scp>). Magnetic Resonance in Medicine, 2018, 80, 1962-1978.	3.0	38
82	Improved Spatiotemporal Resolution of Dynamic Susceptibility Contrast Perfusion MRI in Brain Tumors Using Simultaneous Multi-Slice Echo-Planar Imaging. American Journal of Neuroradiology, 2018, 39, 43-45.	2.4	15
83	Phase 2 and biomarker study of trebananib, an angiopoietinâ€blocking peptibody, with and without bevacizumab for patients with recurrent glioblastoma. Cancer, 2018, 124, 1438-1448.	4.1	38
84	Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143. Neuro-Oncology, 2018, 20, 674-686.	1.2	364
85	D-2-Hydroxyglutarate Is Necessary and Sufficient for Isocitrate Dehydrogenase 1 Mutant–Induced <i>MIR148A</i> Promoter Methylation. Molecular Cancer Research, 2018, 16, 947-960.	3.4	8
86	Evidence and context of use for contrast enhancement as a surrogate of disease burden and treatment response in malignant glioma. Neuro-Oncology, 2018, 20, 457-471.	1.2	44
87	Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy. Neuro-Oncology, 2018, 20, 249-258.	1.2	78
88	Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02. Journal of Neuro-Oncology, 2018, 136, 79-86.	2.9	21
89	Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma. Clinical Cancer Research, 2018, 24, 295-305.	7.0	68
90	Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE. Clinical Cancer Research, 2018, 24, 737-743.	7.0	154

#	Article	IF	CITATIONS
91	Tissue microarray analysis for epithelial membrane protein-2 as a novel biomarker for gliomas. Brain Tumor Pathology, 2018, 35, 1-9.	1.7	12
92	Longitudinal Patterns in Clinical and Imaging Measurements Predict Residual Survival in Glioblastoma Patients. Scientific Reports, 2018, 8, 14429.	3.3	22
93	Mono-exponential, diffusion kurtosis and stretched exponential diffusion MR imaging response to chemoradiation in newly diagnosed glioblastoma. Journal of Neuro-Oncology, 2018, 139, 651-659.	2.9	25
94	Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC. Neuro-Oncology, 2018, 20, 1383-1392.	1.2	135
95	ls it time to reconsider the role of irinotecan for the treatment of high-grade gliomas?. Neuro-Oncology, 2018, 20, 1144-1144.	1.2	3
96	A gene expression signature predicts recurrence-free survival in meningioma. Oncotarget, 2018, 9, 16087-16098.	1.8	26
97	Human <i>TERT</i> promoter mutation enables survival advantage from <i>MGMT</i> promoter methylation in <i>IDH1</i> wild-type primary glioblastoma treated by standard chemoradiotherapy. Neuro-Oncology, 2017, 19, now189.	1.2	65
98	Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas. Journal of Neuro-Oncology, 2017, 132, 181-188.	2.9	16
99	Incidence, survival, pathology, and genetics of adult Latino Americans with glioblastoma. Journal of Neuro-Oncology, 2017, 132, 351-358.	2.9	34
100	Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma. Neuro-Oncology, 2017, 19, now287.	1.2	128
101	Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials. Neurotherapeutics, 2017, 14, 307-320.	4.4	294
102	The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria. Neuro-Oncology, 2017, 19, 625-635.	1.2	137
103	mTORC2 Regulates Amino Acid Metabolism in Cancer by Phosphorylation of the Cystine-Glutamate Antiporter xCT. Molecular Cell, 2017, 67, 128-138.e7.	9.7	147
104	Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II–III diffuse gliomas. Journal of Neuro-Oncology, 2017, 134, 177-188.	2.9	118
105	Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O ⁶ -Methylguanine–DNA Methyltransferase Biomarker Analyses, Journal of Clinical Oncology, 2017, 35, 343-351.	1.6	110
106	Cytoplasmic p53 couples oncogene-driven glucose metabolism to apoptosis and is a therapeutic target in glioblastoma. Nature Medicine, 2017, 23, 1342-1351.	30.7	79
107	Detection of immune responses after immunotherapy in glioblastoma using PET and MRI. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 10220-10225.	7.1	79
108	NovoTTF: where to go from here?. Neuro-Oncology, 2017, 19, 605-608.	1.2	14

7

#	Article	IF	CITATIONS
109	Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials. Clinical Cancer Research, 2017, 23, 5745-5756.	7.0	53
110	Early experience with formalin-fixed paraffin-embedded (FFPE) based commercial clinical genomic profiling of gliomas-robust and informative with caveats. Experimental and Molecular Pathology, 2017, 103, 87-93.	2.1	7
111	Report of safety of pulse dosing of lapatinib with temozolomide and radiation therapy for newly-diagnosed glioblastoma in a pilot phase II study. Journal of Neuro-Oncology, 2017, 134, 357-362.	2.9	22
112	Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials. Neuro-Oncology, 2017, 19, 89-98.	1.2	68
113	NCMP-01. SEIZURE CONTROL AFTER INITIAL PRESENTATION IN IDH MUTATED GLIOMA PATIENTS. Neuro-Oncology, 2017, 19, vi135-vi136.	1.2	1
114	GENE-41. EPIGENETIC DOWN-REGULATION OF THE METALLOTHIONEIN FAMILY IN ISOCITRATE DEHYDROGENASE (IDH) MUTANT GLIOMAS. Neuro-Oncology, 2017, 19, vi101-vi101.	1.2	0
115	Adult Glioblastoma. Journal of Clinical Oncology, 2017, 35, 2402-2409.	1.6	561
116	PD-1 blockade enhances the vaccination-induced immune response in glioma. JCI Insight, 2016, 1, .	5.0	128
117	Single-Cell Phosphoproteomics Resolves Adaptive Signaling Dynamics and Informs Targeted Combination Therapy in Glioblastoma. Cancer Cell, 2016, 29, 563-573.	16.8	140
118	Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio. Neuro-Oncology, 2016, 18, 1313-1318.	1.2	39
119	Large-scale assessment of the gliomasphere model system. Neuro-Oncology, 2016, 18, 1367-1378.	1.2	82
120	Biomarkers in NOA-04: another piece to the puzzle. Neuro-Oncology, 2016, 18, 1467-1469.	1.2	4
121	An LXR-Cholesterol Axis Creates a Metabolic Co-Dependency for Brain Cancers. Cancer Cell, 2016, 30, 683-693.	16.8	237
122	Phase I study of RO4929097 with bevacizumab in patients with recurrent malignant glioma. Journal of Neuro-Oncology, 2016, 130, 571-579.	2.9	39
123	Simulation, phantom validation, and clinical evaluation of fast pHâ€weighted molecular imaging using amine chemical exchange saturation transfer echo planar imaging (CESTâ€EPI) in glioma at 3 T. NMR in Biomedicine, 2016, 29, 1563-1576.	2.8	51
124	Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma. Science Translational Medicine, 2016, 8, 341ra75.	12.4	158
125	Contrastâ€enhancing tumor growth dynamics of preoperative, treatmentâ€naive human glioblastoma. Cancer, 2016, 122, 1718-1727.	4.1	47
126	Bidirectional Contrast agent leakage correction of dynamic susceptibility contrast (DSC)â€MRI improves cerebral blood volume estimation and survival prediction in recurrent glioblastoma treated with bevacizumab. Journal of Magnetic Resonance Imaging, 2016, 44, 1229-1237.	3.4	27

#	Article	IF	CITATIONS
127	Emerging Approaches for Targeting Metabolic Vulnerabilities in Malignant Glioma. Current Neurology and Neuroscience Reports, 2016, 16, 17.	4.2	15
128	The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab. Clinical Cancer Research, 2016, 22, 575-581.	7.0	62
129	Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. Neuro-Oncology, 2016, 18, 557-564.	1.2	432
130	Association between lesion location and language function in adult glioma using voxel-based lesion-symptom mapping. NeuroImage: Clinical, 2015, 9, 617-624.	2.7	23
131	SURG-09RESULTS OF A DOSE ESCALATION TRIAL OF TOCA 511 WITH TOCA FC IN RECURRENT HGG UNDERGOING REPEAT RESECTION. Neuro-Oncology, 2015, 17, v216.1-v216.	1.2	0
132	NIMG-24HIGH SPATIOTEMPORAL DYNAMIC SUSCEPTIBILITY CONTRAST (DSC) PERFUSION MRI USING MULTIBAND ECHOPLANAR IMAGING (MB-EPI). Neuro-Oncology, 2015, 17, v158.4-v159.	1.2	70
133	Bone morphogenetic protein 7 sensitizes O6-methylguanine methyltransferase expressing-glioblastoma stem cells to clinically relevant dose of temozolomide. Molecular Cancer, 2015, 14, 189.	19.2	38
134	Ribosomal Proteins RPS11 and RPS20, Two Stress-Response Markers of Glioblastoma Stem Cells, Are Novel Predictors of Poor Prognosis in Glioblastoma Patients. PLoS ONE, 2015, 10, e0141334.	2.5	52
135	The <i>MGMT</i> promoter SNP rs16906252 is a risk factor for <i>MGMT</i> methylation in glioblastoma and is predictive of response to temozolomide. Neuro-Oncology, 2015, 17, 1589-1598.	1.2	57
136	Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma. Journal of Clinical Oncology, 2015, 33, 2166-2175.	1.6	112
137	GENO-30DISTINCT GENE EXPRESSION PROFILE THAT IS NOT A KNOWN SURVIVAL PREDICTOR IN TUMORS FROM LONG-TERM HIGH GRADE GLIOMA SURVIVORS TREATED WITH A RETROVIRAL REPLICATING VECTOR ENCODING YEAST CYTOSINE DEAMINASE. Neuro-Oncology, 2015, 17, v98.2-v98.	1.2	0
138	IMCT-05COMBINABILITY OF TOCA FC AND TOCA 511 WITH CHEMOTHERAPY AND TARGETED AGENTS. Neuro-Oncology, 2015, 17, v108.1-v108.	1.2	0
139	A novel bicompartmental mathematical model of glioblastoma multiforme. International Journal of Oncology, 2015, 46, 825-832.	3.3	5
140	Patient-specific characterization of the invasiveness and proliferation of low-grade gliomas using serial MR imaging and a mathematical model of tumor growth. Oncology Reports, 2015, 33, 2883-2888.	2.6	5
141	Glucose-dependent acetylation of Rictor promotes targeted cancer therapy resistance. Proceedings of the United States of America, 2015, 112, 9406-9411.	7.1	96
142	2-Hydroxyglutarate Inhibits ATP Synthase and mTOR Signaling. Cell Metabolism, 2015, 22, 508-515.	16.2	190
143	Relationship Between [18F]FDOPA PET Uptake, Apparent Diffusion Coefficient (ADC), and Proliferation Rate in Recurrent Malignant Gliomas. Molecular Imaging and Biology, 2015, 17, 434-442.	2.6	28
144	Quantification of Nonenhancing Tumor Burden in Gliomas Using Effective T2 Maps Derived from Dual-Echo Turbo Spin-Echo MRI. Clinical Cancer Research, 2015, 21, 4373-4383.	7.0	27

#	Article	IF	CITATIONS
145	Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma. Nature Reviews Cancer, 2015, 15, 302-310.	28.4	305
146	pH-weighted molecular imaging of gliomas using amine chemical exchange saturation transfer MRI. Neuro-Oncology, 2015, 17, 1514-1524.	1.2	96
147	Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. Neuro-Oncology, 2015, 17, 1188-98.	1.2	346
148	Radial expansion rates and tumor growth kinetics predict malignant transformation in contrast-enhancing low-grade diffuse astrocytoma. CNS Oncology, 2015, 4, 247-256.	3.0	16
149	Brain Malignancy Steering Committee clinical trials planning workshop: Report from the Targeted Therapies Working Group. Neuro-Oncology, 2015, 17, 180-188.	1.2	28
150	Diffusion MRI Characteristics after Concurrent Radiochemotherapy Predicts Progression-Free and Overall Survival in Newly Diagnosed Glioblastoma. Tomography, 2015, 1, 37-43.	1.8	12
151	Patient-Specific Metrics of Invasiveness Reveal Significant Prognostic Benefit of Resection in a Predictable Subset of Gliomas. PLoS ONE, 2014, 9, e99057.	2.5	89
152	Increased sensitivity to radiochemotherapy in IDH1 mutant glioblastoma as demonstrated by serial quantitative MR volumetry. Neuro-Oncology, 2014, 16, 414-420.	1.2	82
153	Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD). Neuro-Oncology, 2014, 16, vii36-vii47.	1.2	41
154	Pros and cons of current brain tumor imaging. Neuro-Oncology, 2014, 16, vii2-vii11.	1.2	56
155	BI-10 * pH-WEIGHTED MRI IN HUMAN GLIOMAS. Neuro-Oncology, 2014, 16, v25-v25.	1.2	0
156	Recurrent Glioblastoma Treated with Bevacizumab: Contrast-enhanced T1-weighted Subtraction Maps Improve Tumor Delineation and Aid Prediction of Survival in a Multicenter Clinical Trial. Radiology, 2014, 271, 200-210.	7.3	150
157	Glioblastoma: From Molecular Pathology to Targeted Treatment. Annual Review of Pathology: Mechanisms of Disease, 2014, 9, 1-25.	22.4	427
158	Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma. New England Journal of Medicine, 2014, 370, 709-722.	27.0	2,078
159	The procurement, storage, and quality assurance of frozen blood and tissue biospecimens in pathology, biorepository, and biobank settings. Clinical Biochemistry, 2014, 47, 258-266.	1.9	198
160	Tumor-Suppressive miR148a Is Silenced by CpG Island Hypermethylation in <i>IDH1</i> -Mutant Gliomas. Clinical Cancer Research, 2014, 20, 5808-5822.	7.0	30
161	Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors. Neuro-Oncology, 2014, 16, 1541-1546.	1.2	12
162	Emerging function of mTORC2 as a core regulator in glioblastoma: metabolic reprogramming and drug resistance. Cancer Biology and Medicine, 2014, 11, 255-63.	3.0	44

#	Article	IF	CITATIONS
163	PET Parametric Response Mapping for Clinical Monitoring and Treatment Response Evaluation in Brain Tumors. PET Clinics, 2013, 8, 201-217.	3.0	8
164	EGFR Mutation-Induced Alternative Splicing of Max Contributes to Growth of Glycolytic Tumors in Brain Cancer. Cell Metabolism, 2013, 17, 1000-1008.	16.2	130
165	Quantitative probabilistic functional diffusion mapping in newly diagnosed glioblastoma treated with radiochemotherapy. Neuro-Oncology, 2013, 15, 382-390.	1.2	38
166	Functional diffusion maps (fDMs) evaluated before and after radiochemotherapy predict progression-free and overall survival in newly diagnosed glioblastoma. Neuro-Oncology, 2012, 14, 333-343.	1.2	74
167	18F-FDOPA and 18F-FLT positron emission tomography parametric response maps predict response in recurrent malignant gliomas treated with bevacizumab. Neuro-Oncology, 2012, 14, 1079-1089.	1.2	99
168	Differential Sensitivity of Glioma- versus Lung Cancer–Specific EGFR Mutations to EGFR Kinase Inhibitors. Cancer Discovery, 2012, 2, 458-471.	9.4	304
169	Phase 2 trial design in neuro-oncology revisited: a report from the RANO group. Lancet Oncology, The, 2012, 13, e196-e204.	10.7	49
170	Anatomic localization of O6-methylguanine DNA methyltransferase (MGMT) promoter methylated and unmethylated tumors: A radiographic study in 358 de novo human glioblastomas. NeuroImage, 2012, 59, 908-916.	4.2	128
171	Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. Journal of Neuro-Oncology, 2012, 108, 491-498.	2.9	149
172	The Impact of Recent Data on the Optimization of Standards of Care in Newly Diagnosed Glioblastoma. Seminars in Oncology, 2011, 38, S11-S20.	2.2	16
173	Rosette-forming glioneuronal tumor: a pineal region case with IDH1 and IDH2 mutation analyses and literature review of 43 cases. Journal of Neuro-Oncology, 2011, 102, 477-484.	2.9	68
174	ls surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma?. Neuro-Oncology, 2011, 13, 1118-1124.	1.2	100
175	Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab. Neuro-Oncology, 2011, 13, 1151-1161.	1.2	69
176	Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group. Journal of Clinical Oncology, 2010, 28, 1963-1972.	1.6	3,222
177	Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma. Journal of Clinical Oncology, 2009, 27, 4733-4740.	1.6	2,219
178	Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas. Neuro-Oncology, 2008, 10, 162-170.	1.2	362
179	Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma. PLoS Medicine, 2008, 5, e8.	8.4	499
180	The prevalence of favorable PTEN and MGMT biomarker status in 66 glioblastomas. FASEB Journal, 2008, 22, 706,16.	0.5	0

#	Article	IF	CITATIONS
181	Phase II Trial of Tipifarnib in Patients With Recurrent Malignant Glioma Either Receiving or Not Receiving Enzyme-Inducing Antiepileptic Drugs: A North American Brain Tumor Consortium Study. Journal of Clinical Oncology, 2006, 24, 3651-3656.	1.6	151
182	18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy. Journal of Nuclear Medicine, 2006, 47, 904-11.	5.0	293
183	Content Based Image Retrieval for MR Image Studies of Brain Tumors. Annual International Conference of the IEEE Engineering in Medicine and Biology Society, 2006, , .	0.5	0
184	Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. Cancer, 2003, 97, 2381-2386.	4.1	110
185	lrinotecan Treatment for Recurrent Malignant Glioma Using an Every-3-Week Regimen. American Journal of Clinical Oncology: Cancer Clinical Trials, 2002, 25, 204-208.	1.3	39
186	Relationships between choline magnetic resonance spectroscopy, apparent diffusion coefficient and quantitative histopathology in human glioma. Journal of Neuro-Oncology, 2000, 50, 215-226.	2.9	251
187	Inverse correlation between choline magnetic resonance spectroscopy signal intensity and the apparent diffusion coefficient in human glioma. Magnetic Resonance in Medicine, 1999, 41, 2-7.	3.0	150
188	Inverse correlation between choline magnetic resonance spectroscopy signal intensity and the apparent diffusion coefficient in human glioma. Magnetic Resonance in Medicine, 1999, 41, 2-7.	3.0	2
189	Topographic mapping of somatosensory evoked potentials helps identify motor cortex more quickly in the operating room. Brain Topography, 1992, 5, 53-58.	1.8	24